期刊
DRUG DISCOVERY TODAY
卷 25, 期 1, 页码 141-149出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.09.020
关键词
-
资金
- BPI (banque publique d'investissement)
- region of Paris (Paris Region Entreprise)
- French Research Tax Credit program
- ANRT (CIFRE) [2014/0359]
- CIFRE [2016/0747, CIFRE 2013/0364, CIFRE 2015/976]
- Eurostars programs [Nanoneck-2 E9309]
- AIR program (aide a l'innovation responsable) from the region of Paris [A1401025Q]
- ANR (Agence Nationale de la Recherche) Mefisto
- Nomis Foundation
In nanomedicine, iron oxide nanoparticles are at an advanced stage, being commercialized for cancer treatment and iron-deficiency anemia treatment. Their therapeutic efficacy comes from their ability to target a tissue, activate a drug, locally produce a temperature increase following (or not) the application of an external source of energy, modify genes or activate various biological materials, or replace diseased cells by stem cells. Owing to these various mechanisms of action, they can potentially be used for treating a whole range of different diseases, making them more appealing than conventional drugs that target a more limited number of indications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据